Literature DB >> 19214282

All that bleeds is not infliximab-refractory ulcerative colitis.

J K Law1, B Salh, E M Yoshida.   

Abstract

The role of biological agents in moderate to severe ulcerative colitis has been shown to be effective in the induction of clinical remission. However, the role of infliximab therapy for induction of remission in patients with fulminant colitis is debatable. A case of a hospitalized patient with a new diagnosis of severe ulcerative colitis refractory to intravenous steroids is presented. The patient was treated with infliximab and discharged with clinical remission, but subsequently presented back to hospital with a lower gastrointestinal hemorrhage.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19214282      PMCID: PMC2694586          DOI: 10.1155/2009/983121

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  5 in total

1.  Intensive intravenous regimen for severe attacks of ulcerative colitis.

Authors:  S C Truelove; D P Jewell
Journal:  Lancet       Date:  1974-06-01       Impact factor: 79.321

2.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

3.  Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.

Authors:  S L Jakobovits; D P Jewell; S P L Travis
Journal:  Aliment Pharmacol Ther       Date:  2007-05-01       Impact factor: 8.171

4.  Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

Authors:  B E Sands; W J Tremaine; W J Sandborn; P J Rutgeerts; S B Hanauer; L Mayer; S R Targan; D K Podolsky
Journal:  Inflamm Bowel Dis       Date:  2001-05       Impact factor: 5.325

5.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

Authors:  Gunnar Järnerot; Erik Hertervig; Ingalill Friis-Liby; Lars Blomquist; Per Karlén; Christer Grännö; Mogens Vilien; Magnus Ström; Ake Danielsson; Hans Verbaan; Per M Hellström; Anders Magnuson; Bengt Curman
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.